Despite superior efficacy and a manageable side effect profile, Gedatolisib's requirement for weekly IV infusions is its primary drawback. If it were an oral drug, it would be universally adopted for post-CDK4/6 inhibitor breast cancer treatment, as its clinical benefits are otherwise compelling.
Although 22% of patients experienced severe (Grade 3) mucositis, the treatment discontinuation rate due to adverse events was only about 3%. This disparity highlights that the side effect, while serious, was effectively managed with proactive dose reductions, preventing it from being a treatment-limiting factor for most patients.
While initially approved for PIK3CA wild-type patients, Gedatolisib also doubled progression-free survival in patients with PIK3CA mutations compared to the standard of care. This mutation-agnostic benefit simplifies treatment decisions for clinicians, broadens the drug's applicability, and removes the need for mutation-specific testing to determine eligibility.
The next evolution in this drug class involves inhibitors that only target mutated PI3K. This specificity aims to avoid effects on wild-type PI3K, which is involved in insulin signaling. The goal is to dramatically reduce severe side effects like hyperglycemia, which could allow for higher, more effective drug doses.